Get started
TELIX PHARMACEUTICTELIX PHARMACEUTICTELIX PHARMACEUTIC

TELIX PHARMACEUTIC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

TLX1/N chart


Full chart

TLX1/N upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪113.22 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
75.13
Basic EPS (TTM)
1.95 MXN
Net income (FY)
‪643.90 M‬ MXN
Revenue (FY)
‪10.10 B‬ MXN
Shares float
‪267.25 M‬
Beta (1Y)
1.43

About TELIX PHARMACEUTICALS LIMITED


Sector
Health Technology
Industry
Biotechnology
CEO
Christian P. Behrenbruch
Website
telixpharma.com
Headquarters
Melbourne
Founded
2017
ISIN
AU000000TLX2
FIGI
BBG01MFRGWT5
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TLX1/N news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as TLX1/N.

Frequently Asked Questions


The current price of TLX1/N is 138.77 MXN — it hasn't changed in the past 24 hours. Watch TELIX PHARMACEUTIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange TELIX PHARMACEUTIC stocks are traded under the ticker TLX1/N.
TLX1/N stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in TELIX PHARMACEUTIC price.
We've gathered analysts' opinions on TELIX PHARMACEUTIC future price: according to them, TLX1/N price has a max estimate of 453.94 MXN and a min estimate of 367.44 MXN. Watch TLX1/N chart and read a more detailed TELIX PHARMACEUTIC stock forecast: see what analysts think of TELIX PHARMACEUTIC and suggest that you do with its stocks.
TLX1/N reached its all-time high on May 5, 2025 with the price of 138.77 MXN, and its all-time low was 138.77 MXN and was reached on Apr 23, 2024. View more price dynamics on TLX1/N chart.
See other stocks reaching their highest and lowest prices.
TLX1/N stock is 0.00% volatile and has beta coefficient of 1.43. Track TELIX PHARMACEUTIC stock price on the chart and check out the list of the most volatile stocks — is TELIX PHARMACEUTIC there?
Today TELIX PHARMACEUTIC has the market capitalization of ‪113.22 B‬, it has decreased by −4.76% over the last week.
Yes, you can track TELIX PHARMACEUTIC financials in yearly and quarterly reports right on TradingView.
TELIX PHARMACEUTIC is going to release the next earnings report on Aug 21, 2025. Keep track of upcoming events with our Earnings Calendar.
TELIX PHARMACEUTIC revenue for the last quarter amounts to ‪1.89 B‬ MXN, despite the estimated figure of ‪1.89 B‬ MXN. In the next quarter, revenue is expected to reach ‪7.45 B‬ MXN.
TLX1/N net income for the last half-year is ‪261.40 M‬ MXN, while the previous report showed ‪362.57 M‬ MXN of net income which accounts for −27.90% change. Track more TELIX PHARMACEUTIC financial stats to get the full picture.
No, TLX1/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TELIX PHARMACEUTIC EBITDA is ‪1.06 B‬ MXN, and current EBITDA margin is 11.52%. See more stats in TELIX PHARMACEUTIC financial statements.
Like other stocks, TLX1/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TELIX PHARMACEUTIC stock right from TradingView charts — choose your broker and connect to your account.